SURROZEN INC

Surrozen (SRZN) sees heavy insider buying amid a 43.86% upside—strategic ownership boosts confidence but volatility remains high. Learn why investors are bullish yet cautious.

Surrozen (SRZN) posts modest gains after securing a $95 M funding round, boosting runway to 2029 while still chasing its first FDA‑approved retinal therapy milestone.

Surrozen’s 5.45 % rally, backed by a final private placement and FDA clearance, fuels a 52‑week gain and positions the firm for 2029‑ahead clinical milestones.